Cite

APA Citation

    Teeple, A., & Fitzgerald, T. (2022). cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. Journal of dermatological treatment, 33, 518–524. http://access.bl.uk/ark:/81055/vdc_100182129368.0x00002c
  
Back to record